umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Novel mechanisms of ALK activation revealed by analysis of the Y1278S neuroblastoma mutation.
Umeå University, Faculty of Medicine, Department of Molecular Biology (Faculty of Medicine). (Professor Bengt Hallberg)
Institute of Biomedicine,Dept of Medical Biochem and Cell Biol, Sahlgrenska Academy, University of Gothenburg.. (Professor Bengt Hallberg)
Institute of Biomedicine,Dept of Medical Biochem and Cell Biol, Sahlgrenska Academy, University of Gothenburg.. (Professor Ruth H Palmer)
Institute of Biomedicine,Dept of Medical Biochem and Cell Biol, Sahlgrenska Academy, University of Gothenburg.. (Professor Ruth H Palmer)
Show others and affiliations
(English)Manuscript (preprint) (Other academic)
National Category
Natural Sciences Medical and Health Sciences
Identifiers
URN: urn:nbn:se:umu:diva-106700OAI: oai:DiVA.org:umu-106700DiVA: diva2:845379
Note

Authors Damini Chand and Jikui Guan are shared first authors for this manuscript.

Available from: 2015-08-11 Created: 2015-08-03 Last updated: 2015-09-01Bibliographically approved
In thesis
1. Mechanistic Implications and Characterization of Anaplastic Lymphoma Kinase (ALK) mutations in Neuroblastoma
Open this publication in new window or tab >>Mechanistic Implications and Characterization of Anaplastic Lymphoma Kinase (ALK) mutations in Neuroblastoma
2015 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that was first reported as a fusion partner of nucleophosmin in Anaplastic large cell lymphoma in 1994. ALK is involved in myriad of cancers including neuroblastoma which is the most common extracranial solid tumor affecting young children. It arises in the neural crest cells of sympathetic nervous system origin and is responsible for 12% of all childhood cancer deaths. Several point mutations in ALK have been described in both familial and sporadic neuroblastoma.

With the aim to understand the role of ALK in neuroblastoma further, we investigated the point mutations in ALK reported in patients. Using cell culture based methods and Drosophila as a model organism; we first characterized these mutations under three broad categories: 1) Ligand independent mutations that were constitutively active, 2) Kinase dead mutation and 3) Ligand dependent mutations that behaved as inducible wild type. Further, to understand the activation mechanism of ALK, we constructed mutations that could potentially alter ALK’s conformation based on the available crystal structure. From the data generated, we were able to provide a new perspective to the activation of full length ALK receptor. This was more in line with activation mechanism of insulin receptor and different from that suggested for ALK fusion protein. From a clinical point of view, all the mutations in the study were blocked to different degrees using the ALK inhibitor, crizotinib. Lastly, we identified potential downstream targets of ALK using phosphoproteomics. From the various targets identified, we focused on STAT3 and confirmed its role as a mediator in ALK initiated MYCN transcription. We showed that STAT3 inhibition led to reduction of MYCN levels and thereby identifying it as a potential therapeutic target in neuroblastoma. Overall, our study highlights clinical relevance of ALK mutations in neuroblastoma and from a basic biology viewpoint; it reveals important mechanistic insight into receptor activation.

Place, publisher, year, edition, pages
Umeå: Umeå Universitet, 2015. 79 p.
Series
Umeå University medical dissertations, ISSN 0346-6612 ; 1709
Keyword
neuroblastoma, ALK, crizotinib, receptor tyrosine kinase
National Category
Cell and Molecular Biology
Research subject
Molecular Biology
Identifiers
urn:nbn:se:umu:diva-106663 (URN)978-91-7601-254-3 (ISBN)
Public defence
2015-10-02, KBC-huset, Stora hörsalen, KKB3B1, Umeå universitet, Umeå, 09:00 (English)
Opponent
Supervisors
Available from: 2015-09-04 Created: 2015-07-28 Last updated: 2015-09-04Bibliographically approved

Open Access in DiVA

No full text

Authority records BETA

Chand, DaminiRuuth, KristinaHallberg, Bengt

Search in DiVA

By author/editor
Chand, DaminiRuuth, KristinaHallberg, Bengt
By organisation
Department of Molecular Biology (Faculty of Medicine)
Natural SciencesMedical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 232 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf